Navigation Links
Boron-based compounds trick a biomedical protein
Date:9/2/2009

Chemists and biologists have successfully demonstrated that specially synthesized boron compounds are readily accepted in biologically active enzymes, a move that, they say, is a proof of concept that could lead to new drug design strategies.

In June 2008, University of Oregon chemist Shih-Yuan Liu reported in the Journal of the American Chemical Society his lab's synthesis of boron-nitrogen compounds with electronic and structural similarities to fundamentally important benzene molecules. That synthesis suggested a new tool for possible use in biomedical research as well as in materials science.

What Liu's lab created were benzene surrogates known as 1,2-dihydro-1,2-azaborines that possess electron-delocalized structures consistent with aromaticity -- a core concept in chemistry where rings of atoms exhibit unexpected stability.

Now, in the Sept. 1 issue of Angewandte Chemie, a weekly journal of the German Chemical Society, Liu and colleagues show that their synthesized compounds indeed are accepted in non-polarized hydrophobic pockets of a well-studied enzyme, a member of the lysozyme family discovered by Alexander Fleming in 1921 and used widely in biomedical research.

The "proof of concept" was completed in the Institute of Molecular Biology lab of the UO physicist Brian W. Matthews, where Liu's synthesized compound was treated with T4 lysozymes, crystallized and examined with high-resolution X-ray crystallography.

"I feel this is a fairly big step forward," Liu said. "Our compounds bind efficiently to the T4 lysozyme and behave as hydrophobic arene molecules similar to natural systems. Our compound actually has polar features, so it was questionable that it would bind to the enzyme's hydrophobic pocket, but it did and very similarly to the way carbon molecules would bind."

In essence, Liu and colleagues have potentially put boron, a commonly occurring essential nutrient in plants -- but seemingly "bypassed by nature in evolution" of other living things, Liu said -- into play as an alternative to carbon in manufacturing target-specific pharmaceuticals. The use of boron in the biomedical field is not new but its acceptance has been hampered by instability, but interest has risen in the last decade, Liu said.

An analysis of boron's medical potential appeared in the February issue of EMBO Reports. Boron is being studied by a number of drug manufacturers. It currently is used as an antibacterial drug component and as part of a therapy for multiple myeloma. The advance by Liu's lab strengthens the case that boron-based molecules can be used as new pharmacophores, or as markers of drugs in living tissue, and to improve long-stymied attempts to develop boron-neutron capture therapies to produce inhibiting agents for cancer treatment.

"This research provides the first experimental evidence that enzymes in our bodies cannot distinguish between our artificial compound versus the all-carbon systems," Liu said. "We can trick the enzymes to believing they are accepting the real thing."


'/>"/>

Contact: Jim Barlow
jebarlow@uoregon.edu
541-346-3481
University of Oregon
Source:Eurekalert  

Related biology news :

1. Natural compounds, chemotherapeutic drugs may become partners in cancer therapy
2. MSU discoveries upend traditional thinking about how plants make certain compounds
3. Compounds could be new class of cancer drugs
4. Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds
5. 2 new compounds show promise for eliminating breast cancer tumors
6. Two new compounds show promise for eliminating breast cancer tumors
7. Scripps research scientists identify compounds for stem-cell production from adult cells
8. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
9. New $11 million center to speed production of new compounds for drug discovery
10. Discovery of natural compounds that could slow blood vessel growth
11. Duke team finds compounds that prevent nerve damage
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Boron-based compounds trick a biomedical protein
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO ... ASTER Labs ), Inc. has been selected for membership in ARCS Alumni ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
Breaking Biology Technology: